PRAME and acute myeloid leukemia: In addition, PRAME-specific T cells in AML patients who received hematopoietic stem cell transplantation (HSCT) were associated with long-term survival [9,10,11], indicating the suitability of PRAME for T cell recognition and leukemia control.